BIBF1120 (nintedanib)

nintedanib · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BIBF1120 (nintedanib), covering 2015-05-12 to 2015-05-12. Get the full timeline:

Most recent: Clinical Trial Update: BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma [Phase 2]